Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.60 |
| ▸ | DRD1 | P21728 | 2/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.60 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL934635 | 0.91 | HDAC6 (0.59) | DRD2DRD1TAAR1ENPP2HDAC6 | |
| SCHEMBL30692614 | 0.84 | DRD2 (0.59) | DRD2DRD1TAAR1ENPP2HDAC6 | |
| SCHEMBL29822763 | 0.84 | DRD2 (0.59) | DRD2DRD1TAAR1ENPP2HDAC6 | |
| SCHEMBL11756870 | 0.84 | DRD2 (0.59) | DRD2DRD1TAAR1ENPP2HDAC6 | |
| SCHEMBL29563859 | 0.82 | KEAP1 (0.63) | DRD2DRD1TAAR1HDAC6CHRM2 | |
| SCHEMBL65250 | 0.82 | KEAP1 (0.63) | DRD2DRD1TAAR1HDAC6CHRM2 | |
| Phenol SCHEMBL28125145 | 0.82 | KEAP1 (0.57) | HDAC6MAPK1MAPTCAPN1 | |
| SCHEMBL31336237 | 0.82 | KEAP1 (0.63) | DRD2DRD1TAAR1HDAC6CHRM2 | |
| SCHEMBL4604250 | 0.81 | MAOA (0.57) | CYP3A4CAPN1 | |
| SCHEMBL265820 | 0.81 | ALDH1A1 (0.62) | DRD2DRD1TAAR1ENPP2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104356063-A | Preparation method of 7-hydroxy-3,4-dihydro-2-(1H) carbostyril | UNIV EAST CHINA NORMAL | 2015-02-18 | — | — | CN | claimed |
| CN-114790328-B | Alicyclic polycarbonate composition | 华东理工大学 | 2024-03-22 | — | — | CN | disclosed |
| WO-2023226965-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-11-30 | — | — | WO | disclosed |
| CN-109096249-A | A kind of synthetic method of Aripiprazole | 中国科学院兰州化学物理研究所 | 2018-12-28 | — | — | CN | disclosed |
| CN-106905249-A | A kind of preparation method of azepine class compound | 长沙深橙生物科技有限公司 | 2017-06-30 | — | — | CN | disclosed |
| CN-104356063-A | Preparation method of 7-hydroxy-3,4-dihydro-2-(1H) carbostyril | UNIV EAST CHINA NORMAL | 2015-02-18 | — | — | CN | disclosed |
| US-8404859-B2 | Thiazole and thiophene compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| WO-2012123471-A1 | THIAZOLE AND THIOPHENE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| US-20120238569-A1 | THIAZOLE AND THIOPHENE COMPOUNDS | GILLESPIE PAUL (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120107273-A1 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-05-03 | — | — | US | disclosed |
| US-7923578-B2 | Prevent sagging of skin; luster ; amidation of 3-(4-hydroxyphenyl)propionic acid with ammonia using 4-nitrophenol in ethyl acetateand dicyclohexylcarbodiimide; stirring ; precipitation dicyclohexylurea; filtration under vacuum | INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) | 2011-04-12 | — | — | US | disclosed |
| EP-2009004-A1 | NOVEL PIPERAZINE COMPOUND, AND USE THEREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | JAPAN TOBACCO INC. (JP) | 2008-04-03 | — | — | US | disclosed |
| EP-0901483-B1 | BENZOFURANS AND BENZOPYRANS AS CHRONOBIOLOGICAL AGENTS | GLAXO GROUP LTD (GB) | 2003-07-09 | — | — | EP | disclosed |
| US-5981572-A | Benzofurans and benzopyrans as chronobiological agents | GLAXO WELLCOME INC. (US) | 1999-11-09 | — | — | US | disclosed |
| EP-0901483-A2 | BENZOFURANS AND BENZOPYRANS AS CHRONOBIOLOGICAL AGENTS | GLAXO GROUP LIMITED (GB) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997043272-A2 | BENZOFURANS AND BENZOPYRANS AS CHRONOBIOLOGICAL AGENTS | GLAXO GROUP LIMITED (GB) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | HAVCR2, AADAC, DNPEP | DRD2 4595/4885DRD1 4359/4885TAAR1 2335/4885 |
| US-20120107273-A1 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR | POLR1C, POLR2E, POLR2H | DRD2 3613/4885DRD1 3150/4885TAAR1 3452/4885 |
| US-20120238569-A1 | THIAZOLE AND THIOPHENE COMPOUNDS | TSLP, CFTR, TPMT | DRD2 3537/4885DRD1 3672/4885TAAR1 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.